Molecular Biomarkers of Residual Disease after Surgical Debulking of High-Grade Serous Ovarian Cancer
暂无分享,去创建一个
Bulent Ozpolat | Wei Hu | Rajesha Rupaimoole | Anil K Sood | Keith A Baggerly | Cristina Ivan | Robert L Coleman | Gabriel Lopez-Berestein | Jamie Guenthoer | K. Baggerly | A. Unruh | A. Sood | S. Tucker | C. Ivan | Wei Hu | R. Coleman | B. Ozpolat | G. Lopez-Berestein | S. Wu | R. Rupaimoole | A. Nick | K. Gharpure | Susan L Tucker | Heather J Dalton | Sherry Y Wu | Alpa M Nick | H. Dalton | Kshipra Gharpure | Shelley M Herbrich | Anna K Unruh | Erin K Crane | Jamie Guenthoer | E. Crane
[1] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[2] A. Moorman,et al. Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data , 2009, Nucleic acids research.
[3] Tae-Joong Kim,et al. Preoperative serum CA‐125 levels and risk of suboptimal cytoreduction in ovarian cancer: A meta‐analysis , 2010, Journal of surgical oncology.
[4] T. Ince,et al. Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[5] W. Cliby,et al. Aggressive Surgical Effort and Improved Survival in Advanced-Stage Ovarian Cancer , 2006, Obstetrics and gynecology.
[6] H. Ryu,et al. Impact of Complete Cytoreduction Leaving No Gross Residual Disease Associated with Radical Cytoreductive Surgical Procedures on Survival in Advanced Ovarian Cancer , 2012, Annals of Surgical Oncology.
[7] Kenneth P. Nephew,et al. Rethinking ovarian cancer: recommendations for improving outcomes , 2011, Nature Reviews Cancer.
[8] Jacobus Pfisterer,et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials , 2009, Cancer.
[9] G. Scambia,et al. Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial , 2009, British Journal of Cancer.
[10] O. Valenta,et al. Gynecologic oncology , 1990 .
[11] R. Tothill,et al. Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.
[12] G. Mills,et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth , 2011, Nature Medicine.
[13] Terence P. Speed,et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..
[14] W. E. Gye,et al. CANCER RESEARCH , 1923, British medical journal.
[15] Kevin R. Coombes,et al. The Bimodality Index: A Criterion for Discovering and Ranking Bimodal Signatures from Cancer Gene Expression Profiling Data , 2009, Cancer informatics.
[16] David M. Simcha,et al. Tackling the widespread and critical impact of batch effects in high-throughput data , 2010, Nature Reviews Genetics.
[17] Laurent Ozbun,et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. , 2008, Cancer research.
[18] D. Alberts,et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] E. Trimble,et al. Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis. , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] R. Irizarry,et al. A gene expression bar code for microarray data , 2007, Nature Methods.
[21] M. Datto,et al. Genes with bimodal expression are robust diagnostic targets that define distinct subtypes of epithelial ovarian cancer with different overall survival. , 2012, The Journal of molecular diagnostics : JMD.
[22] Z. Hall. Cancer , 1906, The Hospital.
[23] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[24] S. Orsulic,et al. Ovarian Cancer , 1993, British Journal of Cancer.
[25] R. Angioli,et al. Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? , 2013, Gynecologic oncology.
[26] J. Dungan,et al. Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer , 2011 .
[27] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[28] R. Rosenfeld. Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[29] B. Karlan,et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] H. Harashima,et al. RNA interference-based silencing reveals the regulatory role of fatty acid-binding protein 4 in the production of IL-6 and vascular endothelial growth factor in 3T3-L1 adipocytes. , 2012, Endocrinology.
[31] R. Berkowitz,et al. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy. , 2012, Gynecologic oncology.